Incivek for hepatitis C infection is approved in US

The U.S. Food and Drug Administration (FDA) approves Incivek for hepatitis C – The U.S. Food and Drug Administration approved Incivek (telaprevir) to treat certain adults with chronic hepatitis C infection. Incivek is used for patients who have either not received interferon-based drug therapy for their infection or who have not responded adequately to prior therapies.

A new drug may improve Hepatitis C

New drug technology produces marked improvement in hepatitis C therapy in animals – In a dramatic finding, a new drug for hepatitis C virus (HCV) infections that targets liver cells produced a substantial drop in blood levels of the virus in animals and continued to work up to several months after treatment, say scientists at the Southwest Foundation for Biomedical Research (SFBR) in San Antonio.

HIV positive have good survival rate after liver transplant

HIV positive and HIV negative patients have similar survival rates following liver transplant. – HIV positive and HIV negative patients have comparable survival rates following liver transplant, according to new research presented today at EASL 2009, the Annual Meeting of the European Association for the Study of Liver in Copenhagen, Denmark.

New hope for hepatitis C sufferers

Adelaide scientists will lead a $2 million five-year project to develop new vaccines and explore better treatment options for hepatitis C sufferers. – University of Adelaide virologists Dr Michael Beard and Dr Karla Helbig will work with colleagues from the University of NSW to develop new strategies to treat and prevent hepatitis C, which infects more than 170 million people around the world.

Health Newstrack